BUREAU-VERITAS
Regulatory News:
2023 Key Figures1
- Revenue of EUR 5,867.8 million for the full year 2023, up 8.5% organically and up 3.8% on a reported basis (including a positive 0.6% scope effect and a negative 5.3% currency fluctuations)
- In the fourth quarter, organic revenue growth achieved 9.4%
- Adjusted operating profit of EUR 930.2 million, up 3.1% versus EUR 902.1 million in 2022, representing an adjusted operating margin of 15.9%, down c.10 basis points on a reported basis, and up 20 basis points organically at 16.2% (of which +c.50bps in H2 2023)
- Operating profit of EUR 824.4 million, up 3.1% versus EUR 799.3 million in 2022
- Attributable net profit of EUR 503.7 million, up 7.9% versus EUR 466.7 million in 2022
- Adjusted net profit of EUR 574.7 million (adjusted EPS of EUR 1.27 per share), up 7.6% versus EUR 533.9 million in 2022 and up 17.6% at constant currency
- Free cash flow of EUR 659.1 million (11% of Group revenue), up 0.3% year-on-year and 5.5% at constant currency, led by disciplined capex policy and working capital management
- Adjusted net debt/EBITDA ratio2 reduced to 0.92x as of December 31, 2023, versus 0.97x last year
- Proposed dividend of EUR 0.83 per share3, up 7.8% year-on-year, payable in cash
2023 Highlights
- Appointment of a new CEO and strengthening of the Executive Committee to support future growth ambitions
- 2023 financial targets exceeded on all metrics
- Over 80% of the portfolio delivered at least mid-to-high single digit or double-digit organic revenue growth driven by good momentum in the sales pipeline
- Strong growth in every region (Americas, Middle East, Europe, Africa and Asia-Pacific), substantially outperforming many underlying markets
- Strong momentum maintained for Sustainability and energy transition solutions across the entire portfolio
- Acquisition of two bolt-on companies further diversifying Consumer Products Services adding annualized revenue of c. EUR 28 million. This includes ANCE, the leading player in Mexico for Electrical and Electronics products (c. EUR 21 million of revenue), announced today
- Good progress towards the achievement of the 2025 CSR ambitions; commitment recognized by several non-financial rating agencies, including a first ranking in the 2023 S&P Global rating (DJSI); mid-term GHG emissions targets approved by the Science Based Targets initiative (SBTi)
2024 Outlook
Leveraging a healthy and growing sales pipeline, high customer demand for ‘new economy services’ and strong underlying market growth, Bureau Veritas expects to deliver for the full year 2024:
- Mid-to-high single-digit organic revenue growth;
- Improvement in adjusted operating margin at constant exchange rates;
- Strong cash flow, with a cash conversion above 90%.
The Group expects H2 organic revenue growth above H1 (with stronger comparables in H1).
Hinda Gharbi, Chief Executive Officer, commented:
“We delivered very strong results in 2023, reflecting our robust business fundamentals, our consistent execution and our customer centricity around the globe. We achieved organic growth of 8.5%, a healthy organic margin of 16.2%, and record earnings per share of EUR 1.27, up over 17% at constant exchange rates.
I would like to warmly thank all our colleagues around the world for their dedication and hard work to deliver this outstanding performance.
I also want to thank our shareholders for their continued support. As a result of our robust cash flow generation and financials, the Board is recommending a dividend increase of 8% compared to last year.
I am convinced that we can take Bureau Veritas to higher levels of performance and achievement. Our portfolio of leading global business lines, strong execution track record and exposure to positive secular trends are key contributors to our current performance and a great foundation for future outperformance.
Specifically, we expect powerful demand for services supporting transition to sustainable development models, evolving buildings integrity needs, growing infrastructure investment and increased spending in low-carbon energy development. Our current pipeline of opportunities in these business areas is a testament to this durable growth dynamic. I look forward to updating the market with our vision and new strategy at our Capital Markets Day on March 20th.
For 2024, we expect Bureau Veritas to deliver another strong year of organic revenue growth, margin expansion4 and strong cash conversion.”
Click here to download the complete Press Release.
About Bureau Veritas
Bureau Veritas is a world leader in laboratory testing, inspection and certification services. Created in 1828, the Group has circa 82,000 employees located in nearly 1,600 offices and laboratories around the globe. Bureau Veritas helps its 400,000 clients improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 ESG, CAC Next 20, CAC 40 SBT 1.5, and SBF 120 indices. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com, and follow us on Twitter (@bureauveritas) and LinkedIn.
1 Alternative performance indicators are presented, defined and reconciled with IFRS in appendices 6 and 8 of this press release.
2 Ratio of adjusted net financial debt divided by consolidated EBITDA (earnings before interest, tax, depreciation, amortization and provisions), adjusted for any entities acquired over the last 12 months.
3 Proposed dividend, subject to Shareholders’ Meeting approval on June 20, 2024.
4 At constant currency
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221228025/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom